Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Booking Holdings Inc (BKNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Booking Holdings Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $288.59 (market cap $39.89B), while Booking Holdings Inc trades at $175.02 (market cap $138.23B). The key difference: Booking Holdings Inc is far larger — about 3.5× Alnylam Pharmaceuticals, Inc.'s market cap, and Booking Holdings Inc pays a 0.9% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | BKNG | |
|---|---|---|
Market Cap | $39.89B | $138.23B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $231.02 |
52-Week Low | $278.09 | $154.13 |
Enterprise Value | $38.15B | $141.15B |
Dividend Yield | — | 0.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Booking Holdings (BKNG) trades at $178.39, up 1.64% with mixed technical signals showing bearish overall momentum but bullish moving averages. The company maintains strong fundamentals with $26.92B revenue and 22.23% net margin in 2025, though Q2 2026 earnings remain pending. Recent news highlights AI integration efforts and travel demand resilience despite geopolitical concerns.
BKNG presents a compelling valuation case with analyst consensus target of $222.81 (25% upside) and no sell ratings. Key risks include AI disruption fears and Middle East tensions, but the company's dominant OTA position and robust cash flow generation support long-term growth prospects in the travel recovery cycle.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Booking Holdings Inc
Booking is the world's largest online travel agency by revenue, offering booking and payment services for hotel and alternative accommodation rooms, airline tickets, rental cars, restaurant reservations, cruises, experiences, and other vacation packages. The company operates a number of branded travel booking sites, including Booking.com, Agoda, OpenTable, and Rentalcars.com, and has expanded into travel media with the acquisitions of Kayak and Momondo. Transaction fees for online bookings account for the bulk of revenue and profits.
Read more on BKNG →
